TGFβ modulates PTEN expression independently of SMAD signaling for growth proliferation in colon cancer cells

Cancer Biology and Therapy

Volumn 7, Issue 10, 2008, Pages 1694-1699

  Chow, Jimmy Y C ^a   Cabral, Jennifer A ^a   Chang, Jessica ^a   Carethers, John M ^a,b,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Colonic cancer; PI3K; PTEN; SMAD; Transforming growth factor

Indexed keywords

MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P85; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; PTEN PROTEIN, HUMAN; RNA; SMAD1 PROTEIN; SMAD1 PROTEIN, HUMAN; SMAD4 PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL NUCLEUS TRANSPLANTATION; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; FUNCTIONAL PROTEOMICS; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; COLON TUMOR; DOMINANT GENE; ENZYME ACTIVATION; METABOLISM; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, DOMINANT; HUMANS; PTEN PHOSPHOHYDROLASE; RNA; RNA, MESSENGER; SIGNAL TRANSDUCTION; SMAD1 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 54349117710     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.10.6665     Document Type: Article

References (42)

1. Massague J and Wotton D. Transcriptional control by the TGFbeta/Smad signaling system. Embo J 2000; 19:1745-54.
2. Ten Dijke P and Hill CS. New insights into TGFbeta-Smad signalling. Trends Biochem Sci 2004; 29:265-73.
3. Montgomery E, Goggins M, Zhou S, Argani P, Wilentz R, Kaushal M, Booker S, Romans K, Bhargava P, Hruban R and Kern S. Nuclear localization of Dpc4 (Madh4, Smad4) in colorectal carcinomas and relation to mismatch repair/transforming growth factor-beta receptor defects. Am J Pathol 2001; 158:537-42.
4. Venkatasubbarao K, Ahmed MM, Swiderski C, Harp C, Lee EY, McGrath P, Mohiuddin M, Strodel W and Freeman JW. Novel mutations in the polyadenine tract of the transforming growth factor beta type II receptor gene are found in a subpopulation of human pancreatic adenocarcinomas. Genes Chromosomes Cancer 1998; 22:138-44.
5. Jonson T, Gorunova L, Dawiskiba S, Andren-Sandberg A, Stenman G, ten Dijke P, Johansson B and Hoglund M. Molecular analyses of the 15q and 18q SMAD genes in pancreatic cancer. Genes Chromosomes Cancer 1999; 24:62-71.
6. Takenoshita S, Tani M, Mogi A, Nagashima M, Nagamachi Y, Bennett WP, Hagiwara K, Harris CC and Yokota J. Mutation analysis of the Smad2 gene in human colon cancers using genomic DNA and intron primers. Carcinogenesis 1998; 19:803-7.
7. Xu J and Attisano L. Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 2000; 97:4820-5.
8. Tsushima H, Kawata S, Tamura S, Ito N, Shirai Y, Kiso S, Imai Y, Shimomukai H, Nomura Y, Matsuda Y and Matsuzawa Y. High levels of transforming growth factor beta1 in patients with colorectal cancer: association with disease progression. Gastroenterology 1996; 110:375-82.
9. Massague J. TGFbeta signaling: receptors, transducers and Mad proteins. Cell 1996; 85:947-50.
10. Pasche B. Role of transforming growth factor beta in cancer. J Cell Physiol 2001; 186:153-68.
11. Roberts AB and Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 2003; 100:8621-3.
12. Li W, Qiao W, Chen L, Xu X, Yang X, Li D, Li C, Brodie SG, Meguid MM, Hennighausen L and Deng CX. Squamous cell carcinoma and mammary abscess formation through squamous metaplasia in Smad4/Dpc4 conditional knockout mice. Development 2003; 130:6143-53.
13. Takaku K, Oshima M, Miyoshi H, Matsui M, Seldin MF and Taketo MM. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell 1998; 92:645-56.
14. Takaku K, Wrana JL, Robertson EJ and Taketo MM. No effects of Smad2 (madh2) null mutation on malignant progression of intestinal polyps in Apc(delta716) knockout mice. Cancer Res 2002; 62:4558-61.
15. Jung B, Smith EJ, Doctolero RT, Gervaz P, Alonso JC, Miyai K, Keku T, Sandler RS and Carethers JM. Influence of target gene mutations on survival, stage and histology in sporadic microsatellite unstable colon cancers. Int J Cancer 2006; 118:2509-13.
16. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH and Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275:1943-7.
17. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH and Tavtigian SV. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997; 15:356-62.
18. Maehama T and Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998; 273:13375-8.
19. Di Cristofano A and Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000; 100:387-90.
20. Simpson L and Parsons R. PTEN: life as a tumor suppressor. Exp Cell Res 2001; 264:29-41.
21. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C and Parsons R. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997; 16:64-7.
22. Marsh DJ, Dahia PL, Zheng Z, Liaw D, Parsons R, Gorlin RJ and Eng C. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet 1997; 16:333-4.
23. Huang SC, Chen CR, Lavine JE, Taylor SF, Newbury RO, Pham TT, Ricciardiello L and Carethers JM. Genetic heterogeneity in familial juvenile polyposis. Cancer Res 2000; 60:6882-5.
24. Carethers JM. Unwinding the heterogeneous nature of hamartomatous polyposis syndromes. Jama 2005; 294:2498-500.
25. Dong JT, Sipe TW, Hyytinen ER, Li CL, Heise C, McClintock DE, Grant CD, Chung LW and Frierson HF Jr. PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate. Oncogene 1998; 17:1979-82.
26. Li DM and Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 1997; 57:2124-9.
27. Ebert MP, Fei G, Schandl L, Mawrin C, Dietzmann K, Herrera P, Friess H, Gress TM and Malfertheiner P. Reduced PTEN expression in the pancreas overexpressing transforming growth factor-beta1. Br J Cancer 2002; 86:257-62.
28. Chow JY, Quach K, Cabrera BL, Cabral J, Beck SE and Carethers JM. RAS/ERK Modulates TGF{beta}-regulated PTEN Expression In Human Pancreatic Adenocarcinoma Cells. Carcinogenesis 2007; 28:2321-7.
29. Zhou XP, Loukola A, Salovaara R, Nystrom-Lahti M, Peltomaki P, de la Chapelle A, Aaltonen LA and Eng C. PTEN mutational spectra, expression levels and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol 2002; 161:439-47.
30. Goel A, Arnold CN, Niedzwiecki D, Carethers JM, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM and Boland CR. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res 2004; 64:3014-21.
31. Goel A, Arnold CN, Tassone P, Chang DK, Niedzwiecki D, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM and Boland CR. Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers. Int J Cancer 2004; 112:754-9.
32. Chen SJ, Yuan W, Mori Y, Levenson A, Trojanowska M and Varga J. Stimulation of type I collagen transcription in human skin fibroblasts by TGFbeta: involvement of Smad 3. J Invest Dermatol 1999; 112:49-57.
33. Virolle T, Adamson ED, Baron V, Birle D, Mercola D, Mustelin T and de Belle I. The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling. Nat Cell Biol 2001; 3:1124-8.
34. Choy L, Skillington J and Derynck R. Roles of Autocrine TGF{beta} Receptor and Smad Signaling in Adipocyte Differentiation J. Cell Biol 2000; 149:667-82.
35. Taniguchi CM, Tran TT, Kondo T, Luo J, Ueki K, Cantley LC and Kahn CR. Phosphoinositide 3-kinase regulatory subunit p85{alpha} suppresses insulin action via positive regulation of PTEN. PNAS 2006; 103:12093-7.
36. Fink SP, Mikkola D, Willson JK and Markowitz S. TGFbeta-induced nuclear localization of Smad2 and Smad3 in Smad4 null cancer cell lines. Oncogene 2003; 22:1317-23.
37. Muraoka-Cook RS, Shin I, Yi JY, Easterly E, Barcellos-Hoff MH, Yingling JM, Zent R and Arteaga CL. Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Oncogene 2006; 25:3408-23.
38. Chow JY, Dong H, Quach KT, Van Nguyen PN, Chen K and Carethers JM. TGFbeta mediates PTEN suppression and cell motility through calcium-dependent PKC-alpha activation in pancreatic cancer cells. Am J Physiol Gastrointest Liver Physiol 2008; 294:899-905.
39. Yi JY, Shin I and Arteaga CL. Type I transforming growth factor beta receptor binds to and activates phosphatidylinositol 3-kinase. J Biol Chem 2005; 280:10870-6.
40. Seoane J, Le HV, Shen L, Anderson SA and Massague J. Integration of Smad and Forkhead Pathways in the Control of Neuroepithelial and Glioblastoma Cell Proliferation. Cell 2004; 117:211.
41. Runyan CE, Schnaper HW and Poncelet AC. The Phosphatidylinositol 3-Kinase/Akt Pathway Enhances Smad3-stimulated Mesangial Cell Collagen I Expression in Response to Transforming Growth Factor-{beta}1. J Biol Chem 2004; 279:2632-9.
42. Wilkes MC, Mitchell H, Penheiter SG, Dore JJ, Suzuki K, Edens M, Sharma DK, Pagano RE and Leof EB. Transforming Growth Factor-{beta} Activation of Phosphatidylinositol 3-Kinase Is Independent of Smad2 and Smad3 and Regulates Fibroblast Responses via p21-Activated Kinase-2. Cancer Res 2005; 65:10431-40.